New York, New York (PRWEB) December 26, 2013
Johnson & Johnson continues to fight an effort by plaintiffs in Risperdal lawsuits (http://www.risperdallawsuitcenter.com/ ) to procure the release of certain documents produced during discovery as part of a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to a brief dated December 16th, the company contends that the plaintiffs’ bid to unseal the documents constitutes a “smear campaign,” and that the clinical studies should remain sealed as per a 2011 court order. (In Re: Risperdal Litigation, Case Number 100300296)
According to courts documents, the release of the studies are being sought by plaintiffs in Risperdal lawsuits that allege the drug caused men and boys to develop gynecomastia, or male breast growth. They assert that the studies cannot be considered proprietary, as they include observations about the safety and effectiveness of Risperdal. Plaintiffs have also claimed that the release of the data contained in the studies would be in the public interest.
“Our Firm has heard from a number of individuals concerned about the possible link between Risperdal and gynecomastia, and we continue to investigate these claims. We are monitoring this litigation very closely, and look forward to additional progress in the year to come,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently evaluating Risperdal lawsuits on behalf of men and boys who may have developed gynecomastia due to their use of the drug.
Risperdal Gynecomastia Allegations
According to court documents, more than 200 Risperdal lawsuits have been filed in the Pennsylvania litigation on behalf of plaintiffs who allegedly suffered serious side effects, including gynecomastia, due to their use of the atypical antipsychotic. All of the lawsuits alleging an association between Risperdal and male breast growth claim that Johnson & Johnson and its Janssen Pharmaceuticals unit concealed this risk from doctors and patients. The lawsuits further allege that the companies improperly promoted the use of Risperdal in children before it received regulatory clearance for such indications.
The U.S. Department of Justice announced on November 4, 2013 that it had reached an agreement with Johnson & Johnson and Janssen to settle criminal and civil charges regarding the marketing of Risperdal and other drugs. According to court documents filed in the case, the Justice Department had accused Johnson & Johnson and Janssen of concealing the possible association between Risperdal and gynecomastia. The companies also faced charges that they had improperly engaged in off-label marketing of Risperdal, including promotion of the use of the drug in children. Under the settlement, Johnson & Johnson will pay a total of $2.5 billion in criminal and civil penalties. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who may have developed gynecomastia due to their use of Risperdal could be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com